US FDA Launches Study Of Prescriber Perceptions About Abuse-Deterrent Opioids
Executive Summary
The agency is assessing whether to use different language to describe addiction and abuse deterrence.
You may also be interested in...
Unintended Consequences Of Broad Opioid-Sparing Claims Worries US Panel
FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices.
Mallinckrodt's Abuse Deterrent Oxycodone IR Narrowly Wins US FDA Panel Backing
"Incremental" step forward is sufficient for product to be labeled as deterring abuse by nasal, but not intravenous route, advisory committee members conclude.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.